Item 8.01Other Events.

On January 29, 2021, Turning Point Therapeutics, Inc. (the "Company") issued a press release providing program updates, including reporting updated interim data from the registrational Phase 2 TRIDENT-1 study of the Company's lead drug candidate repotrectinib, in patients with ROS1-positive, tyrosine kinase naïve, non-small cell lung cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.




Exhibit
  No.      Description

99.1         Press Release issued by Turning Point Therapeutics, Inc. on January 29,
           2021.

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses